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Introduction
Although there is strong genetic evidence suggesting autoimmunity in type 1 narcolepsy [1] [2] [3] , notably a 97% association with human leukocyte antigen (HLA) class II alleles DQB1
Ã 06:02 and DQA1
Ã 01:02 that together form the heterodimer DQ0602 [4] , the nature of the autoimmune antigen leading to hypocretin cell death has been elusive. Renewed interest in this area came from the observation of increased incidence of type 1 narcolepsy following the 2009-2010 winter vaccination campaign against the pandemic H1N1 (pH1N1) "swine" flu (pH1N1-2009) that emerged in 2009 [5] . This effect was mostly obvious in Scandinavia, where vaccine coverage with a specific adjuvant system 03 (AS03) (composed of α-tocopherol, squalene and polysorbate 80) adjuvanted vaccine Pandemrix 1 from GlaxoSmithKline (GSK) was high (~50%), and rapid onset narcolepsy was frequently observed in children within a few months following vaccination [5] [6] [7] [8] [9] [10] . In Finland, where incidence of narcolepsy was best estimated and most consistent with known population prevalence (0.02%) [11] , risk of Pandemrix 1 induced narcolepsy increased~10 fold, although absolute risk of developing narcolepsy still remained low (less than 10 for 100,000 vaccinees versus (vs) 0.7 for 100,000 baseline incidences) [12] . Others also found that the onset of narcolepsy was frequently seasonal [13] , occurring in spring or summer, and following winter upper-airway infections such as Streptococcus Pyogenes [14, 15] . Observation of seasonality of onset was more obvious in young children where narcolepsy onset is very abrupt and can more easily be timed to the exact month. All together, these data strongly suggest that narcolepsy is an autoimmune disease triggered by upper airway infections, notably influenza and maybe Streptococcus Pyogenes, with stronger susceptibility to pH1N1-2009. Additional surprising or inconsistent observations were made thereafter. First, whereas in China, a clear increase in childhood narcolepsy cases was observed in ecological studies of two sleep centers during the winter of 2009-2010 [13, 16, 17] , a weaker effect was observed in Germany [18] and in the United States [19, 20] . Second, increased onset of narcolepsy independent of vaccination was not observed in Scandinavia [21] , although this could be due to herd immunity protection against pH1N1 through the high coverage vaccination campaign. Third, Pandemrix 1 vaccination-induced narcolepsy seemed to have occurred more frequently in some areas of Sweden, notably in the south of the country, possibly reflecting differential timing of the infection vs the vaccination campaign, or possible differences between vaccine batches [22, 23] . Fourth, other pH1N1 vaccines were not associated with increased risk of developing narcolepsy, notably in the United States, where only sporadic cases have been reported after flu vaccinations. As only unadjuvanted or live attenuated vaccines were used during the 2009-2010 vaccination campaign in the United States, this suggests that adjuvant AS03 played a role in Pandemrix 1 vaccination-induced narcolepsy. Surprisingly, however, two other adjuvanted pH1N1 vaccines used in countries other than Scandinavia had little or no effects: one is MF59C.1 (containing squalene, polysorbate 80 and sorbitan trioleate) adjuvanted Focetria 1 from Novartis used in Europe (mostly in Italy) [24] , the other is Arepanrix 1 used in Canada and South America [25] , another AS03 adjuvanted vaccine from GSK that is almost identical to Pandemrix 1 except for the method of antigen isolation.
Risk of narcolepsy remained low even with Pandemrix 1 vaccination in 2009-2010 and DQ0602 positive. Indeed, narcolepsy occurred in vaccinated individuals with an incidence of less than 1/3,000 persons after Pandemrix 1 even in DQ0602 positive individuals. The reason for that narcolepsy incidence rate following pH1N1 vaccination varied across vaccines is likely multifactorial, and may involve vaccine composition differences (adjuvant and antigen isolation protocol), prior immune history and genetics of targeted populations. It is notable that some targeted subgroups were prioritized in each vaccination campaign (children vs adults, high risk groups) and that timing of vaccination in relation to the unfolding pandemic flu occurred in close temporal successions, usually within a few weeks in many countries. Nonetheless, one of the most reliable findings may be that Pandemrix 1 had strong effects in most
European countries [26] [27] [28] [29] [30] [31] , and that Arepanrix 1 , a closely related vaccine had less or no effects in Quebec and Canada, suggesting that differences in vaccine composition are involved, as suggested by Ahmed et al. [32] .
Following on these observations, several authors went on to compare the composition of known pH1N1 monovalent vaccines, with primary focus on Pandemrix 1 and Arepanrix 1 , the two most closely related vaccines with differential risks [33] . The creation of flu vaccine is a long process that involves growing genetically engineered flu strains in Gallus gallus (chicken) eggs, and purifying vaccine particles and antigens for vaccine preparation, with primary focus on Hemagglutinin (HA) and Neuraminidase (NA), two surface proteins that are strongly involved in lymphocyte B cell antibody (Ab) responses to the flu [34] [35] [36] [37] . The pH1N1-like vaccine strains X-179A and X-181 were created in New York Medical College (NYMC) for the 2009-2010 swine flu campaign, using an old H1N1-1918-like strain, A/ Puerto Rico/8/1934 (PR8), as a backbone, and reassorted with A/California/07/2009 [38] . In both X-179A and X-181 strains, HA, NA and polymerase (basic) protein 1 (PB1) were derived from A /California/07/2009, while other proteins were PR8-derived [39, 40] . NYMC X-181, characterized by a mutation of HA 146N to 146D and a few other differences (including HA titer, yield of purified viral protein) [41] , was created in late 2009 and selected because it produced higher reassortant HA titers than X-179A. It was used toward the end of the season (2009) in some cases [38] [39] [40] . Both Pandemrix 1 and Arepanrix 1 were produced by GSK using X-179A, while and Arepanrix 1 (a 2010 batch) using MS and showed results obtained with five main viral proteins: HA1 and HA2 subunits of HA, NA, NP, matrix protein 1 (M1), and non-viral proteins from chicken growth matrix [33] . Overall, these vaccines were remarkably similar. , and found that Arepanrix 1 reacted poorly with antibodies of post Pandemrix 1 vaccinated children, suggesting antigenic differences in antibody determinants [42] . Increased antibody levels to HA and NP, particularly to structurally altered viral NP, were also seen in post Pandemrix 1 narcoleptic children [42] . The authors went on to hypothesize that the higher amount of denatured NP in Pandemrix 1 during the purification process of viral proteins may explain increased narcolepsy susceptibility with Pandemrix 1 vaccination.
Following on these observations, Ahmed et al. identified a sequence of NP 111-121 (YDKEEIRRIWR) with NP 116I (underlined) in X-179A with significant homology to a sequence of the first extracellular domain of HCRTR2 (HCRTR2 [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] , YDDEEFLRYLWR), whereas a mutation of NP 116I to 116M in NP 111-121 (YDKEEMRRIWR, 116M was underlined) was found in Focetria
1
, which in any case contained only very limited amount of NP because of its specific subunit compositions [43] . The authors also found anti-HCRTR2 autoantibodies were detectable in post Pandemrix 1 narcolepsy patients (17 of 20 sera), but not in subjects (0 of 12 sera) after Focetria 1 vaccination in 2009.
This article raised two interesting points: (1) the possibility of amino acid residue mutations, such as NP 116I to 116M in some vaccine strains, may influence vaccine response and mimicry; (2) a possible role of anti-HCRTR2 autoantibodies in the pathophysiology of narcolepsy [43] . In this study, we further evaluated these hypotheses by (1) examining the prevalence of NP 116I and 116M in Pandemrix 
Materials and methods

Ethics statement
This study was reviewed and approved by the Stanford University Institutional Review Board (Protocol # 14325, Registration # 5136). Informed consent was obtained from each participant.
Participants
Two groups of matched narcolepsy patients and controls were created. All patients meet international classification of sleep disorders 3 (ICSD3) criteria (http://www.aasmnet.org/ store/product.aspx?pid=849) for type 1 narcolepsy and were DQ0602 positive with one exception, a patient known to have low cerebrospinal fluid (CSF) hypocretin-1 levels (S1 Table) . Narcolepsy patients included 40 
Mass spectrometry (MS)
Detailed protocols have been published previously [33] . Briefly, MS was performed on Trypsin/Lys-C mix (Cat# V5073, Promega) and chymotrypsin (Cat# V1062, Promega) digests of Pandemrix [33, 43] . All statistical analyses were performed on raw data and were undertaken using Cochran-Mantel-Haenszel chi square tests using RStudio 3.1.0, using mantelhaen.test and cmh.test functions [46] .
HA and NP peptides binding to DQ0602 monomers
Complementary deoxyribonucleic acid (cDNA) templates of HLA-DQA1 Ã 01:02 and DQB1
Ã 06:02 were obtained from the Emory University NIH core tetramer facility (http:// tetramer.yerkes.emory.edu/support/faq). Soluble DQ0602 monomers were expressed in "high five" cell line (a gift from K. Christopher Garcia lab, Stanford University) and purified using fast protein liquid chromatography (FPLC). The CLIP peptide, which derives from the major histocompatibility complex (MHC) class II-associated invariant chain (li), was removed by cleavage with thrombin (Cat# 69671, EMD Millipore). CLIP plays a critical role in the assembly of MHC, especially for antigen processing by stabilizing peptide-free DQ0602 complex [47] [48] [49] . Another nonclassical MHC class II heterodimer molecule, HLA-DM, which regulates and catalyzes antigenic peptide loading onto DQ0602 [50, 51] , was also expressed in "high five" cell line and purified. Peptides were ordered at GenScript company with >90% purity and dissolved in dimethyl sulfoxide (DMSO) at stock concentration of 10 mM.
Peptide competing binding assays were conducted by incubation of 25 nM DQ0602, 100 nM HLA-DM, 1 μM biotin-conjugated Epstein-Barr virus (EBV) epitope (Bio-EBV, Bio-GGGRALLARSHVERTTDE), with 40 μM of the competitor peptide in reaction buffer (100 mM acetate, pH = 4.6, 150 mM NaCl, 1% BSA, 0.5% Nonidet P-40 (IGEPAL CA-630, Sigma), 0.1% NaN 3 ) in duplicate for 3 days at 37˚C. The reaction was quenched by adding two volumes of neutralization buffer (100 mM Tris-HCl, pH = 8.6, 150 mM NaCl, 1% BSA, 0.5 Nonidet P-40 (IGEPAL CA-630, Sigma), 0.1% NaN 3 ). Monoclonal anti-DQ (SPV-L3) antibodies (Cat# BNUM0200-50, Biotium) (1:400 dilution in 100 mM carbonate-bicarbonate buffer, pH = 9.5) were coated onto a high binding 96-well plate (REF# 9018, Corning), and incubated with neutralized reaction for 1-2 hour at room temperature (RT). After washing five times with 300 μl/ well of wash buffer (phosphate-buffered saline (PBS), 0.05% Tween-20, pH = 7.4), 100 μl/well of Europium (Eu)-labelled streptavidin (Cat# 1244-360, PerkinElmer) (1:1000 dilution in PBS, 1% BSA, pH = 7.4) was added and incubated for 1 hour at RT. After washing 5 times again ADE2908 and AFM7284 were identical to AIE525 and AFM7285, respectively. AIE5269 and ADE2909 displayed six amino acid residue differences (two in NP and four in nonstructural protein 1 (NS1)).
with 300 μl/well of wash buffer, DELFIA 1 time-resolved fluorescence (TRF) intensity was detected using a Tecan Infinite 1 M1000 after adding 100 μl/well of enhancement solution (Cat# 1244-105, PerkinElmer). Non-specific binding was removed through extensive wash with wash buffer. Competitor peptide with Eu TRF intensity that was lower than 25% of Bio-EBV epitope alone was considered strong binder, while peptide with 25-50% was weak binder.
HCRTR2 constructs
For HCRTR2 transcription and translation in vitro, plasmid pCMV3-HA-HCRTR2 was purchased from Sino Biological Inc. (Cat# HG10844-NY-HCRTR2). For immunofluorescence observation and flow cytometry analysis, construct pcDNA3.1-HCRTR2-GFP was generated as follows: coding sequence (CDS) of HCRTR2 was amplified with high fidelity Platinum 1 Taq DNA polymerase (Cat# 11304011, ThermoFisher Scientific) (forward primer, 5'-GTGATG TCCGGCACCAAAT-3', reverse primer, 5'-CCCAGTTTTGAAGTGGTCCTG-3') using plasmid pCMV3-HA-HCRTR2 as template and then fused to N terminus of the green fluorescent protein (GFP) gene using a CT-GFP fusion TOPO 1 TA cloning kit (Cat# K482001, ThermoFisher Scientific). The insertion was confirmed by deoxyribonucleic acid (DNA) sequencing.
Anti-HCRTR2 autoantibody detection with flow cytometry
HEK293T cells (purchased from ATCC, https://www.atcc.org/Products/All/CRL-3216.aspx) [52, 53] were cultured in Dulbecco's modified Eagle's medium (DMEM) (ATCC Table) . Methods for quantitation analysis have been described previously [54, 55] Table) . 12 random sera, including 6 patients and 6 controls, with five dilution ratios from 1:50 to 1:800 in reaction buffer were also tested (S3 Table) . All sera were diluted at 1:50 for quantitation as follows: 1 μL of serum was incubated with 20,000 cpm of [ Anti-HCRTR2 autoantibody detection using in-cell ELISA
In-cell ELISA colorimetric assay was performed according to the manufacturer's instructions (Cat# 62200, ThermoFisher Scientific). CHO-HCRTR2 cell line was made in a CHO-K1 host cell line (purchased from ATCC, https://www.atcc.org/products/all/CCL-61.aspx) [57, 58] Table) . Briefly, 10,000 live CHO-HCRTR2 cells/well were plated in a black collagen I-coated 96-well plate (REF# 152035, ThermoFisher Scientific), and cultured overnight at 37˚C, 5% CO 2 . Cells were fixed with 4% formaldehyde (Cat# 28906, ThermoFisher Scientific) for 15 minutes at 4˚C in the dark, followed by blocking overnight at 4˚C with 200 μL/well of blocking buffer (included in kit After transferring proteins from the gel to an Immobilon 1 -P membrane (Cat# IPVH00010, EMD Millipore) and blocking the membrane with a blocking buffer (Cat# 37543, ThermoFisher Scientific), the primary anti-HCRTR2 antibody (Cat# WH0003062M1-100UG, SigmaAldrich) (1:500 dilution) was incubated for 2 hours at RT, followed by incubation with a secondary, peroxidase-conjugated, anti-mouse IgG (H+L) antibody (Code# 715-035-150, Jackson ImmnuoResearch Laboratories, Inc.) (1:5000 dilution). Non-specific binding was removed through washing 3 times for 10 minutes (PBS, 0.05% Tween-20). Chemiluminescent substrate (Prod# 32106, ThermoFisher Scientific) was applied to the blot following the manufacturer's instructions. Chemiluminescence film (Product code# 28906838, GE Healthcare) was developed using a tablet film processor (Item# SRX-101A, Konica).
Cell-base assay (CBA) for anti-HCRTR2 autoantibody detection under microscope HEK293T cells (purchased from ATCC, https://www.atcc.org/Products/All/CRL-3216.aspx) [52, 53] imaging system (Cat# AMF4300, ThermoFisher Scientific). All antibodies were diluted in saturation buffer and non-specific binding was removed through extensive wash 3 times with PBS.
Statistical analyses
For MS analysis, categorical values were expressed as percentages, linear values as mean ± SD or standard error. Data were analyzed using SAS software (SAS Institute Inc.) with two-sided t-tests. P-value <0.05 was considered statistically significant. For anti-HCRTR2 autoantibody analysis and peptide binding assay, values were expressed as mean ± SD, and statistical comparisons were calculated using two-tailed t-tests in Microsoft Excel. Data were plotted using GraphPad PRISM 5 (GraphPad Software, Inc.). P-value <0.05 was considered statistically significant.
Results
NP 116M was predominantly present in all vaccines tested
Spectrograms were mapped on a library of peptides generated from the trypsin and chemotrypsin digests of X-179A and X-181 with accession numbers ADE2909 (March 2010), AIE5269 (May 2014), and AFM7284 (June 2012) (Fig 1, Table 1, S5 Fig, S9- Table) . the positive anti-HCRTR2 antibody bound to the extracellular domain of HCRTR2 and gave a strong staining signal using Alexa Fluor 1 555 (AF555) channel (Fig 3A) . (Fig 3A-3D, S1 Fig, S2 Table) . Among the 176 subjects tested (S6 and S7 Figs, S20 (Fig 3I and 3K , S20 Table) , suggesting presence of anti-HCRTR2 autoantibodies in these three sera. Low ΔMFI AF555 was also observed in five other subjects (Fig 3F-3H , 3J and 3L, S20 Table) , with lower ΔMFI 
Differential analysis of anti-HCRTR2 autoantibody between narcolepsy patients and controls
To further analyze potential differences in anti-HCRTR2 autoantibody concentrations between narcolepsy patients and controls, the MFI AF555 index used to quantify anti-HCRTR2 Table) .
Anti-HCRTR2 autoantibody detection using [
S]-radiolabelled HCRTR2 and in-cell ELISA
We further tested anti-HCRTR2 autoantibodies with the same samples using both [ Table) with repeat (88 subjects) (S22 Table) or in the corrected OD450 of human IgG binding (p-value = 0.7335; mean ± SD: patients, 1.44 ± 1.63; controls, 1.51 ± 1.25) (Panel C in S10 Fig, S7 Table) with repeat (S8 Table) . Three controls showed positive reactions with higher anti-HCRTR2 autoantibody index above cut-off value (2.45), including one PP-C control (autoantibody index, 2.81) and two O-C controls (autoantibody indexes. 2.59, 2.64), and all narcolepsy patients showed negative reactions (Fig 4B, Panel B in  S10 Fig, Table 3 , S3 Table) . Also, positive reactions of human IgG binding to HCRTR2 were detected within two EO-N patients (OD450, 6.29, 13.51), one PP-C control (OD450, 6.49), and one O-C control (OD450, 5.98), accorded to the cut-off value (5.26) (Fig 4C, Panel C in  S10 Fig, Table 3 , S7 Table) .
No positive reaction was found in PP-N patients with each of these three different methods (Fig 4, Table 3 , S3, S7 and S20 Tables). No significant difference was found either between PP-N patients and matched PP-C controls or between EO-N patients and matched O-C controls with each of the three tests, except for the former pairs in in-cell ELISA (p-value = 0.0399) (Fig 4,  Table 3 , S3, S7 and S20 Tables). Any other subject which showed positive reaction with one test was found negative with other two methods (Fig 4, Table 3 , S3, S7 and S20 Tables). No known factor was positively correlated to these positive subjects (Table 3) .
Discussion
This work shows that anti-HCRTR2 autoantibodies were rarely detected (3 or 4 positive reactions of 176 sera), with no positive subject found in post Pandemrix 1 narcolepsy patients (PP-N). We were unable to confirm that anti-HCRTR2 autoantibodies were present in a large portion of the population, extending on the work in 191 samples recently published by Giannoccaro et al. [61] , who used HEK293 cells transiently transfected with human HCRTR2 and scored each serum stained with HEK293 cells, and found 3 of 61 patients positive: two type 1 narcolepsy and one type 2 narcolepsy, but none of the control subjects. In our study, to maximize the possibility of finding positives, we tested 40 post Pandemrix 1 narcolepsy cases and 18 matched controls (similar to those used in the Ahmed et al. [43] ), plus 48 sera of patients who had a very recent onset ( 6 months) of narcolepsy. The last group was selected because of the highest likelihood the autoimmune process would still have been active in these patients, and thus detection of autoantibody would be the easiest. With CBA detection described by Giannoccaro et al. [61] , positive staining was not observed with positive anti-HCRTR2 antibody (S11 Fig) . Therefore, detection of anti-HCRTR2 autoantibodies was performed using three other independent techniques, one of which was similar to that used by Ahmed et al. [43] (in-cell ELISA) except for the use of a different cell line, CHO-K1 instead of Chem-1. The use of the CHO-K1 cell line was due to the fact that the stably transfected Chem-1-HCRTR2 cell line could not be made available to us. The second technique, [
35 S]-radiolabelled HCRTR2 binding assay, had been previously reported by Tanaka et al. [56] , who could not find evidence for anti-HCRTR2 autoantibodies. Using this second technique, we confirmed this observation (Fig 4, Table 3, S10 Fig, S3 and S22 Tables). The disadvantage of this method was that in vitro No anti-HCRTR2 autoantibodies in narcolepsy translated polypeptide chain was unlikely to be conformationally similar to HCRTR2 that was naturally embedded in cytoplasmic membranes. Because of the limitations of these two techniques (different cell line and conformational difference), we also used a third, more novel technique, which involved HEK293T cells transiently transfected with HCRTR2-GFP. Cells that were double labeled with GFP and anti-HCRTR2 antibody could be easily visualized in the upper right quadrant and distinguished from background or cells that have not successfully expressed the transgene. This last method, which has to our knowledge only been used by a few investigators, such as for the detection of MUC1-Tn antibodies [55] , or N-methyl-Daspartate receptor (NMDAR) or dopamine-2 receptor (D2P) autoantibodies [54] , was found to be more sensitive (see positive controls in Fig 3 and S1 Fig) and yielded a fewer positives in both narcolepsy patient and control subjects (Fig 3, Table 3 , S1 Fig, S2 Table) . Like the in-cell ELISA, this last technique should be targeting a normally conformed HCRTR2. As noted in Table 3 , a few positives were found with one or another technique, but none of the sera reacted positively using all the three techniques. Although these results were disappointing, it was also notable that the presence of anti-HCRTR2 autoantibodies in some narcolepsy patients and controls reported by Ahmed et al. [43] was unlikely to be causative to the condition. Indeed, in narcolepsy, the cells containing the hypocretin ligand, not those carrying hypocretin receptors, were the targets of the autoimmune process. Hypocretin receptors were expressed on a large number of target neurons in the brain [62] , and one would have had to hypothesize some special vulnerability for hypocretin cells to be destroyed by an anti-HCRTR2 process. Further, as discussed by Vassali and Tafti [63] , hypocretin receptors are likely not present on hypocretin cells.
This report also allowed for the clarification of the HA sequence at position 146 and NP sequence at position 116 in these vaccines, and the ability of these sequences to bind to DQ0602. Regarding HA 146N, the fact that the pH1N1 wild-type sequence HA 143-155 (HDSNKGVTAACPH) (146N was underlined) was present in Pandemrix Table) , a result that was predicted by bioinformatics in our prior publication [33] . Surprisingly, however, whereas information provided by Novartis has indicated that Focetria 1 used in the vaccination campaign was primarily derived from X-181, in this study we found that the predominant residue at 146 position was N (Table 2) bility. In spite of multiple efforts, however, we have been unable to find homology for this sequence with known hypocretin neuron proteins [64] [65] [66] .
Regarding the NP 116I, unlike in the wild-type PR8 NP (H1N1-1918-like) sequence, it appeared that this residue has been mutated from I to M in the X-179A strain that has been used for production of not only Pandemrix Table) suggested this epitope was likely irrelevant to DQ0602-associated narcolepsy or differential vaccine risk. Regarding the antibody cross-reactivity previously reported with this epitope by Ahmed et al. [43] , and the fact that could not be reproduced here, explanations could be advanced. Weak antibody cross-reactivity between infectious targets and self-proteins may not be as rare as anticipated. For example, a few years ago, in a study of anti-streptococcal antibodies in narcolepsy, we found that anti-streptolysin (ASO) antibodies, observed more frequently in recent onset narcolepsy sera, cross-reacted weakly with the human phosphodiisomerase (PDI) protein [14, 67] . This result was initially exciting to us, however, we rapidly found these autoantibodies to be present in both ASO-positive narcolepsy patients and controls tempering our enthusiasm. Similarly, Deloumeau et al. [68] reported autoantibodies against hypocretin instead of the HCRTR2 as immune complexes, observations that were only seen in post chemical treatment sera, a finding that has not been reproduced to date.
In conclusion, in this comprehensive study we confirmed that mutations could accumulate in specific flu vaccines as they were propagated in eggs, deviating from the original strain sequence. The presence of one specific mutation in Arepanrix 1 , HA 146D, was confirmed in multiple batches used in Canada. Unfortunately, we were not able to use those batches that were used in Scandinavia in 2009-2010. Theoretically there was a possibility that they may have differed from the batches we studied. Skowronski et al. [69] similarly found that key antigenic residues were mutated in H3N2 reassortant vaccine strains and that this likely contributed to reduced efficacy in 2012-2013. These results suggest that regular DNA sequencing or MS characterization of viral isolates may be useful as quality control measures across long periods of production. We also found that previously reported results suggesting molecular mimicry between NP and HCRTR2 could not be reproduced and that autoreactivity by autoantibodies to HCRTR2 was unlikely to play a role in the pathophysiology of narcolepsy. 
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